# Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

> **NCT01240382** · PHASE3 · COMPLETED · sponsor: **Santen Pharmaceutical Co., Ltd.** · enrollment: 332 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** 3% DE-089 ophthalmic solution
- **DRUG:** 0.1% sodium hyaluronate ophthalmic solution

## Key facts

- **NCT ID:** NCT01240382
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2008-02
- **Final completion:** —
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01240382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01240382, "Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01240382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*